BIIB023

Phase 2Biologic

Biogen

BIIB023 is one of 97 biologic programs targeting Atrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtrophyActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Lupus NephritisActive, not recruiting

AtrophyPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Lupus NephritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Cimzia

30 5

Simponi

Johnson & Johnson

Preclinical

19 6

Remicade

OOrganon and Co

Preclinical

43 7

Enbrel

IImmunex

Preclinical

64 8

Arcoxia

Novartis

Preclinical

4 9

Ilaris

Novartis

Preclinical

3 10

Actos

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lupus Nephritis2 trials

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

Terminated· Biogen logo

Biogen·Phase 2·NCT01499355·276 enrolled

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Terminated· Biogen logo

Biogen·Phase 2·NCT01930890·87 enrolled

Phase 11 trial

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Completed· Biogen logo

Biogen·Phase 1·NCT01407406·48 enrolled

Rheumatoid Arthritis1 trial

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

Completed· Biogen logo

Biogen·Phase 1·NCT00771329·53 enrolled

Atrophy1 trial

A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers

Completed· Biogen logo

Biogen·Phase 1·NCT01943513·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for BIIB023. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIIB023 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIIB023. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Biogen

BIIB023

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lupus Nephritis2 trials

Phase 11 trial

Rheumatoid Arthritis1 trial

Atrophy1 trial

References

Drug Info

Quick Facts

Related News